TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
TScan Therapeutics (Nasdaq: TCRX) announces a virtual KOL event to discuss data from their ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and their clinical development strategy. The event, scheduled for December 10 at 8:00 a.m. ET, will review preliminary results of TSC-100 and TSC-101 in patients with AML, ALL, and MDS undergoing allogeneic hematopoietic cell transplantation. The company will also provide updates on their PLEXI-T™ Phase 1 solid tumor trial and discuss potential registrational pathways following their FDA meeting.
TScan Therapeutics (Nasdaq: TCRX) annuncia un evento virtuale con i KOL per discutere i dati del loro trial ematologico di Fase 1 ALLOHA™ presentati al Meeting Annuale ASH e la loro strategia di sviluppo clinico. L'evento, programmato per il 10 dicembre alle 8:00 a.m. ET, esaminerà i risultati preliminari di TSC-100 e TSC-101 in pazienti con AML, ALL e MDS sottoposti a trapianto di cellule ematopoietiche allogeniche. L'azienda fornirà anche aggiornamenti sul loro trial di Fase 1 PLEXI-T™ sui tumori solidi e discuterà possibili percorsi di registrazione dopo il loro incontro con la FDA.
TScan Therapeutics (Nasdaq: TCRX) anuncia un evento virtual KOL para discutir los datos de su ensayo de fase 1 ALLOHA™ en hematología presentados en la Reunión Anual de ASH y su estrategia de desarrollo clínico. El evento, programado para el 10 de diciembre a las 8:00 a.m. ET, revisará los resultados preliminares de TSC-100 y TSC-101 en pacientes con AML, ALL y MDS sometidos a trasplante de células hematopoyéticas alogénicas. La compañía también proporcionará actualizaciones sobre su ensayo de fase 1 PLEXI-T™ en tumores sólidos y discutirá posibles rutas de registro tras su reunión con la FDA.
TScan Therapeutics (Nasdaq: TCRX)는 ASH 연례 회의에서 발표된 ALLOHA™ 1상 혈액암 시험 데이터와 임상 개발 전략을 논의하기 위해 가상 KOL 이벤트를 발표했습니다. 12월 10일 오전 8:00 ET에 예정된 이번 이벤트에서는 AML, ALL 및 MDS로 고형 세포 이식(Allogeneic Hematopoietic Cell Transplantation)을 받는 환자에서 TSC-100 및 TSC-101의 초기 결과를 검토할 예정입니다. 또한 이 회사는 PLEXI-T™ 1상 고형 종양 시험에 대한 업데이트를 제공하고 FDA 회의 이후 등록 경로를 논의할 것입니다.
TScan Therapeutics (Nasdaq: TCRX) annonce un événement virtuel KOL pour discuter des données de leur essai hématologique de Phase 1 ALLOHA™ présentées lors de la Réunion Annuelle ASH et de leur stratégie de développement clinique. L'événement, prévu pour le 10 décembre à 8h00 ET, passera en revue les résultats préliminaires de TSC-100 et TSC-101 chez des patients atteints d'AML, d'ALL et de MDS subissant une transplantation cellulaire hématopoïétique allogénique. L'entreprise fournira également des mises à jour sur leur essai PLEXI-T™ de Phase 1 sur les tumeurs solides et discutera des voies d'enregistrement potentielles à la suite de leur réunion avec la FDA.
TScan Therapeutics (Nasdaq: TCRX) kündigt eine virtuelle KOL-Veranstaltung an, um Daten aus ihrer ALLOHA™ Phase 1 Hämotherapie-Studie, die auf dem ASH-Jahrestreffen präsentiert wurden, sowie ihre klinische Entwicklungsstrategie zu besprechen. Die Veranstaltung, die für den 10. Dezember um 8:00 Uhr ET angesetzt ist, wird die vorläufigen Ergebnisse von TSC-100 und TSC-101 bei Patienten mit AML, ALL und MDS, die sich einer allogenen hämatopoetischen Zelltransplantation unterziehen, überprüfen. Das Unternehmen wird auch Updates zu seiner PLEXI-T™ Phase 1 Studie zu soliden Tumoren geben und mögliche Zulassungswege nach ihrem Treffen mit der FDA diskutieren.
- Initial FDA meeting completed regarding potential registrational pathway
- Multiple ongoing Phase 1 trials in both heme and solid tumors showing pipeline progress
- None.
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and the clinical development strategy for the heme program. Additionally, the Company will provide an update on its PLEXI-T Phase 1 solid tumor trial. The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET.
The event will provide an in-depth review of the oral presentation describing the preliminary results from TScan’s ongoing ALLOHA Phase 1 heme trial of TSC-100 and TSC-101 in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning. The Company will also provide updates with regards to a potential registrational path for the program following its initial meeting with the U.S. Food and Drug Administration (FDA), as well as future plans to expand the program.
Featured speakers include:
- Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Columbia University Irving Medical Center
- Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
- Chrystal U. Louis, M.D., Chief Medical Officer, TScan Therapeutics
- Shrikanta Chattopadhyay, M.D., Senior Vice President, Head of Translational Medicine, TScan Therapeutics
Registration for the live event can be found here. A replay will be made available on the “Events and Presentations” section of the Company’s investor relations website at ir.tscan.com.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHATM Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers and is enrolling patients into its ongoing PLEXI-T Phase 1 solid tumor trial.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
What will be discussed at TScan Therapeutics (TCRX) December 10 KOL event?
What cancer types are being studied in TScan Therapeutics' (TCRX) ALLOHA Phase 1 trial?
When will TScan Therapeutics (TCRX) host its virtual KOL event?
